{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:11:57Z","timestamp":1778933517642,"version":"3.51.4"},"reference-count":73,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite, A Gilead Company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,3,3]]},"DOI":"10.1080\/14796694.2026.2633443","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:30:30Z","timestamp":1772735430000},"page":"683-698","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8881-8867","authenticated-orcid":false,"given":"Philip K.","family":"Chan","sequence":"first","affiliation":[{"name":"Inovalon, Inc","place":["Bowie, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1955-8253","authenticated-orcid":false,"given":"Markqayne","family":"Ray","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company","place":["Santa Monica, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1103-2107","authenticated-orcid":false,"given":"Karl M.","family":"Kilgore","sequence":"additional","affiliation":[{"name":"Inovalon, Inc","place":["Bowie, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Inovalon, Inc","place":["Bowie, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-8077","authenticated-orcid":false,"given":"Christie","family":"Teigland","sequence":"additional","affiliation":[{"name":"Inovalon, Inc","place":["Bowie, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5618","authenticated-orcid":false,"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Medical Center","place":["Hackensack, USA"]},{"name":"Hackensack Meridian School of Medicine","place":["Nutley, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"2","key":"e_1_3_8_2_1","first-page":"97","article-title":"Follicular lymphoma: a focus on Current and emerging therapies","volume":"36","author":"Cahill KE","year":"2022","unstructured":"Cahill KE, Smith SM. Follicular lymphoma: a focus on Current and emerging therapies. Oncol (Williston Park). 2022;36(2):97\u2013106.","journal-title":"Oncol (Williston Park)"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278766"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278717"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145407"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717738740"},{"key":"e_1_3_8_9_1","volume-title":"StatPearls [Internet]","author":"Singh D","year":"2025","unstructured":"Singh D, Singh A, Mukkamalla SKR. Relapsed and refractory follicular lymphoma [updated 2023 Jan 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589677\/"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01052-3"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2020.16784"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_3_8_13_1","unstructured":"National Comprehensive Cancer Network. B-Cell Lymphomas (Version 5.2022-July 12 2022). 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2171994"},{"key":"e_1_3_8_15_1","volume-title":"Yescarta (axicabtagene ciloleucel) [package insert]","year":"2021","unstructured":"Yescarta (axicabtagene ciloleucel) [package insert]. Foster City (CA): Gilead Sciences; 2021."},{"key":"e_1_3_8_16_1","unstructured":"Kymriah (tisagenlecleucel) [package insert]. Cambridge (MA): Novartis; 2022."},{"key":"e_1_3_8_17_1","unstructured":"Aministration USFa D. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma"},{"key":"e_1_3_8_18_1","volume-title":"Breyanzi (Lisocabtagene Maraleucel) [package insert]","year":"2024","unstructured":"Breyanzi (Lisocabtagene Maraleucel) [package insert]. New York (NY): Bristol Myers Squibb; 2024."},{"key":"e_1_3_8_19_1","unstructured":"Yescarta axicabtagene ciloleucel product information: European medicines agency. 2021 [2024 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta"},{"key":"e_1_3_8_20_1","unstructured":"Ryan C. Axi-cel gains European approval for relapsed\/refractory follicular lymphoma. 2022 [cited 2024 Aug 1]. Available from: https:\/\/www.onclive.com\/view\/axi-cel-gains-european-approval-for-relapsed-refractory-follicular-lymphoma"},{"key":"e_1_3_8_21_1","unstructured":"Excellence NIfHaC. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. 2023 [cited 2024 Aug 1]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta894\/resources\/axicabtagene-ciloleucel-for-treating-relapsed-or-refractory-follicular-lymphoma-pdf-82613794084549"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285245"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170469"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184653"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0173"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70025"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002118"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.3.262"},{"key":"e_1_3_8_29_1","unstructured":"Inovalon Inc. [cited 2024 May 5]. Available from: https:\/\/www.inovalon.com\/lp\/real-world-data\/"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.17.00002"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1228924"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1509320"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1734592"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0607"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.04.017"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1041"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2022.38070"},{"key":"e_1_3_8_38_1","volume-title":"Approaches to algorithm development for the estimation of lines of therapy in oncology using real-world data","author":"Nguyen C","year":"2022","unstructured":"Nguyen C, Hess LM, Nepal B, editors. Approaches to algorithm development for the estimation of lines of therapy in oncology using real-world data. Vienna, Austria: ISPOR Europe; 2022."},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082311"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00125"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879643"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.09.011"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145741"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.3205"},{"key":"e_1_3_8_45_1","unstructured":"MY 2020 HEDIS\u00ae Calculation Specifications. 2020 [cited 2024 Dec 6]. Available from: https:\/\/www.ncqa.org\/wp-content\/uploads\/2020\/11\/HEDIS_CalculationSpecification_MY2020.pdf"},{"key":"e_1_3_8_46_1","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index. 2024 Sep 30. Available from: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm#:~:text=The%20medical%20care%20index%20is professional%20services%2C%20and%20hospital%20services"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23978"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000517"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S432963"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.1.72"},{"key":"e_1_3_8_51_1","unstructured":"MEDPAC Payment Basics. [cited 2024 Dec 1]. Available from: https:\/\/www.medpac.gov\/document-type\/payment-basic\/"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.12.017"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00551-1"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_8_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"e_1_3_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_8_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008097"},{"key":"e_1_3_8_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393939"},{"key":"e_1_3_8_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201611"},{"key":"e_1_3_8_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912"},{"key":"e_1_3_8_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136834"},{"key":"e_1_3_8_62_1","unstructured":"Broderick JM. Axi-cel efficacy in R\/R indolent non-hodgkin lymphoma sustained at 5 years. 2024 [cited 2024 Dec 12]. Available from: https:\/\/www.targetedonc.com\/view\/axi-cel-efficacy-in-r-r-indolent-non-hodgkin-lymphoma-sustained-at-5-years"},{"key":"e_1_3_8_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_3_8_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9"},{"key":"e_1_3_8_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361"},{"key":"e_1_3_8_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w"},{"key":"e_1_3_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.022"},{"issue":"13","key":"e_1_3_8_69_1","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel JY","year":"2021","unstructured":"Spiegel JY, Dahiya S, Jain MD, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;137(13):1832\u20131835.","journal-title":"Blood"},{"key":"e_1_3_8_70_1","doi-asserted-by":"publisher","DOI":"10.46989\/001c.115793"},{"key":"e_1_3_8_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412002"},{"key":"e_1_3_8_72_1","volume-title":"Comparing the demographics of enrollees in medicare advantage and fee-for-service medicare","author":"Murphy-Barron C","year":"2020","unstructured":"Murphy-Barron C, Pyenson B, Ferro C, et al. Comparing the demographics of enrollees in medicare advantage and fee-for-service medicare. Milliman Inc.; 2020 Oct. Available from: https:\/\/bettermedicarealliance.org\/wp-content\/uploads\/2020\/10\/Comparing-the-Demographics-of-Enrollees-in-Medicare-Advantage-and-Fee-for-Service-Medicare-202010141.pdf"},{"key":"e_1_3_8_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/JAC.0000000000000107"},{"key":"e_1_3_8_74_1","volume-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): b-Cell lymphomas version 5","author":"National Comprehensive Cancer Network","year":"2022","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): b-Cell lymphomas version 5. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2022. Available from: https:\/\/www.nccn.org"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2633443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:32:30Z","timestamp":1778931150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2633443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,3]]}},"alternative-id":["10.1080\/14796694.2026.2633443"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2633443","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}